ArticleJournal of immunology (Baltimore, Md. : 1950)2018
Cutting Edge: Intracellular IFN-β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Immunopathogenesis of Systemic Lupus Erythematosus: Interplay of Innate and Adaptive Immunity, Microbiome Dysbiosis, and Emerging Therapeutic Targets.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Review
- IL-4 alters TLR7-induced B cell developmental program in lupus.Clinical immunology (Orlando, Fla.) · 2025Article
- Mitochondrial mass and mitochondrial membrane potential of peripheral lymphocytes: promising biomarkers of systemic lupus erythematosus.Frontiers in molecular biosciences · 2025Article
- Autoimmune Responses and Therapeutic Interventions for Systemic Lupus Erythematosus: A Comprehensive Review.Endocrine, metabolic & immune disorders drug targets · 2024Review
- Increased development of T-betClinical immunology (Orlando, Fla.) · 2023Article
- Interrelation of T cell cytokines and autoantibodies in systemic lupus erythematosus: A cross-sectional study.Clinical immunology (Orlando, Fla.) · 2023Article
- Inhibition of miRNA associated with a disease-specific signature and secreted via extracellular vesicles of systemic lupus erythematosus patients suppresses target organ inflammation in a humanized mouse model.Frontiers in immunology · 2023Article
- IL-4 receptor blockade is a global repressor of naïve B cell development and responses in a dupilumab-treated patient.Clinical immunology (Orlando, Fla.) · 2022Article
- IL-4-Induced Quiescence of Resting Naive B Cells Is Disrupted in Systemic Lupus Erythematosus.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- CD4Lupus science & medicine · 2022Article
- Lupus nephritis correlates with B cell interferon-β, anti-Smith, and anti-DNA: a retrospective study.Arthritis research & therapy · 2022Article
- Regulation of B Cell Responses in SLE by Three Classes of Interferons.International journal of molecular sciences · 2021Review
- Low-Density Neutrophils in Systemic Lupus Erythematosus.Arthritis & rheumatology (Hoboken, N.J.) · 2020Review
- Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study.EClinicalMedicine · 2020Article
- The Plasticity of Newly Formed B Cells.Journal of immunology (Baltimore, Md. : 1950) · 2019Review
- Autoreactive B cells in SLE, villains or innocent bystanders?Immunological reviews · 2019Review
- Review
- Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN.Journal of autoimmunity · 2019Article
- Metformin Inhibits the Type 1 IFN Response in Human CD4Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- PD-1 immunobiology in systemic lupus erythematosus.Journal of autoimmunity · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In systemic lupus erythematosus (SLE), type I IFNs promote induction of type I IFN-stimulated genes (ISG) and can drive B cells to produce autoantibodies. Little is known about the expression of distinct type I IFNs in lupus, particularly high-affinity IFN-β. Single-cell analyses of transitional B cells isolated from SLE patients revealed distinct B cell subpopulations, including type I IFN producers, IFN responders, and mixed IFN producer/responder clusters. Anti-Ig plus TLR3 stimulation of SLE B cells induced release of bioactive type I IFNs that could stimulate HEK-Blue cells. Increased levels of IFN-β were detected in circulating B cells from SLE patients compared with controls and were significantly higher in African American patients with renal disease and in patients with autoantibodies. Together, the results identify type I IFN-producing and -responding subpopulations within the SLE B cell compartment and suggest that some patients may benefit from specific targeting of IFN-β.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.